PFS Partners’s enGene Therapeutics ENGN Stock Holding History

PFS Partners’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$80K	Buy	40,000 +29,000	+264%	+$53.6K	0.03%	162
2026 Q2	$19K	Hold	11,000	–	–	0.01%	311
2026 Q1	$74.9K	Hold	11,000	–	–	0.03%	144
2025 Q4	$99.3K	Buy	11,000 +2,000	+22%	+$16K	0.05%	126
2025 Q3	$61.5K	Buy	+9,000	New	+$41K	0.03%	156

Other funds holding ENGN

Peapod Lane Capital Bedford Hills, New York $134M AUM 63.91% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

PFS Partners's ENGN Position: Q3 2026 in Review

PFS Partners increased its enGene Therapeutics (ENGN) stake by 264% in Q3 2026, buying an estimated $53.6K and bringing the position to 40,000 shares worth $80K. The position accounts for 0.03% of the portfolio, ranked #162.

PFS Partners first reported a position in ENGN in Q3 2025 and has held it in 5 quarters since. The position peaked at $99.3K in Q4 2025. 4 funds tracked by Wall St. Rank hold ENGN as of Q3 2026.

PFS Partners held 40,000 shares of enGene Therapeutics worth $80K as of Q3 2026.
PFS Partners bought 29,000 enGene Therapeutics shares in Q3 2026, an estimated $53.6K.
enGene Therapeutics made up 0.03% of PFS Partners's portfolio in Q3 2026, its #162 holding.
PFS Partners first reported a position in enGene Therapeutics in Q3 2025 and has held it in 5 quarters since.
PFS Partners's enGene Therapeutics position peaked at $99.3K in Q4 2025.
4 funds tracked by Wall St. Rank held enGene Therapeutics as of Q3 2026.

Based on PFS Partners's 13F filing for Q3 2026, filed 21 Oct 2026.